|Day Low/High||0.98 / 1.01|
|52 Wk Low/High||0.38 / 1.59|
PL-8177 Evaluated in Animal Models of Inflammatory Bowel Disease and Autoimmune Uveitis; PL-8331 Evaluated in an Animal Model of Dry Eye
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: PNNT, PTN, VTSI Downgrades: BRN, CNCE, CRWS, DFIN, FF, HDSN, NRT, PFLT, WPM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
NDA includes data from two successful Phase 3 trials in HSDD in premenopausal women in which bremelanotide met the pre-specified co-primary efficacy endpoints
Here's a technical look at how to trade some of the most active stocks on the market right now.
Palatin appears be to playing a game of bait and switch with the design of its phase III studies.
Stocks with insider trader activity include AEL, PTN and BSX
Palatin Technologies (PTN) shares are rising after the FDA approved the first treatment for low female libido earlier this week.
Palatin Technologies (PTN) shares are climbing after the FDA approved the first low female libido treatment yesterday.
Trade-Ideas LLC identified Palatin Technologies (PTN) as a strong on high relative volume candidate
Palatin Technologies (PTN) shares are up over 30% after an FDA advisory panel voted to approve a version of the company's low female libido treatment.
These under-$10 stocks are within range of triggering breakout trades.
TheStreet highlights 3 stocks pushing the Drugs industry lower today.
Clinical Operations experts from Palatin Technologies, Inc. (NYSE MKT: PTN) and PHT Corporation will present on the effective use of eCOA Systems for clinical research on Female Sexual Dysfunction (FSD) at the...
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
These stocks look ready to break out and trade higher from current levels.
Palatin Technologies' CEO Discusses F4Q12 Results - Earnings Call Transcript
Palatin Technologies' CEO Discusses F3Q2012 Results - Earnings Call Transcript
Palatin Technologies' CEO Discusses F2Q2012 Results - Earnings Call Transcript
Palatin Technologies CEO Discusses F1Q12 Results - Earnings Call Transcript
Palatin Technologies CEO Discusses F4Q2011 Results - Earnings Call Transcript
Palatin Technologies CEO Discusses F3Q2011 Results - Earnings Call Transcript
Palatin Technologies CEO Discusses Q4 2010 Results - Earnings Call Transcript
Palatin Technologies CEO Discusses F1Q2011 Results - Earnings Call Transcript
TheStreet Ratings released rating changes on 14 U.S. common stocks for September 29, 2010. Just four stocks were downgraded and 10 stocks have been upgraded by our stock model.
Palatin CEO Discusses F4Q2010 Results - Earnings Call Transcript
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.